PARP inhibition: A promising therapeutic target in ovarian cancer

Cellular and Molecular Biology

Volumn 61, Issue 6, 2015, Pages 44-61

  Musella, A ^a   Marchetti, C ^a   Gasparri, M L ^a   Salerno, L ^a   Casorelli, A ^a   Domenici, L ^a   Imperiale, L ^a   Ruscito, I ^a   Abdul Halim, T ^b   Palaia, I ^a   Di Donato, V ^a   Pecorini, F ^a   Monti, M ^a   Muzii, L ^a   Panici, P B ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b RLMC   (Pakistan)

Author keywords

Ovarian cancer; Parp inhibitors; Synthetic lethality 1; Target therapies

Indexed keywords

INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; TALAZOPARIB; VELIPARIB; BRIDGED COMPOUND; TAXANE; TAXOID;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED CLINICAL TRIAL (TOPIC); DNA REPAIR; DRUG METABOLISM; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HUMAN; MULTICENTER STUDY (TOPIC); ONCOGENE; OVARY CANCER; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FEMALE; METABOLISM; OVARIAN NEOPLASMS;

ANIMALS; BRIDGED COMPOUNDS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; TAXOIDS;

EID: 84962173003     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.6.8     Document Type: Article

References (97)

1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, and Beller U. Carcinoma of the Ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006; 95: S161-192
2. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, John-son N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; Neoadjuvant chemotherapy or primary sur-gery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 10:943-53. doi: 10.1056/NEJMoa0908806.
3. Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S. Monoclonal antibodies the-rapies for ovarian cancer. Expert Opin Biol Ther. 2013; 13:739-64. doi: 10.1517/14712598.2013.767328.
4. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K and Noda K; Japanese Gynecologic Oncology Group. Dose e-dense pacli-taxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374: 1331-8. doi: 10.1016/S0140-6736(09)61157-0.
5. Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Ga-sparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Pa-Nici P, Nuti M. Past, present and future strategies of immunotherapy in gynecological malignancies. Curr Mol Med. 2013; 13:648-69.
6. Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P and Nuti M. Current know-ledge and open issues regarding bevacizumab in gynaecological ne-oplasms. Crit. Rev. Oncol. Hematol. 2012; 83: 35-46. doi: 10.1016/j.critrevonc.2011.09.006.
7. Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F and Benedetti Panici P. Olaparib, PARP1 inhibitor in ovarian cancer. Expert. Opin. Investig. Drugs. 2012; 21: 1575-84.
8. Hall M1, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G and Kaye S. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br. J. Cancer. 2013; 108: 250-8. doi: 10.1038/bjc.2012.541.
9. Fong PC1, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH and de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009; 361: 123-34. doi: 10.1056/NEJ-Moa0900212.
10. Chambon P, Weill JD and Mandel P. Nicotinamide mononucleo-tide activation of new DNA-dependent polyadenylic acid synthesiz-ing nuclear enzyme. Biochem. Biophys. Res. Commun. 1963; 11: 39-43.
11. Alderson T. New targets for cancer chemotherapy: poly (ADP-ribosylation) processing and polyisoprene metabolism. Biol. Rev. 1990; 65: 623-41.
12. Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A and Albanell J. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann. Oncol. 2012; 23: 1156-64. doi: 10.1093/annonc/mdr361.
13. Dinh P, Harnett P,Piccart-Gebhart MJ and Awada A. New thera-pies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit. Rev. Oncol. Hematol. 2008; 67: 103-12. doi: 10.1016/j.cri-trevonc.2008.01.012.
14. Szabó C, Zingarelli B, O'Connor M and Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of mac-rophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. USA 1996; 93: 1753-8.
15. de Murcia JM1, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P and de Murcia G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U S A. 1997; 94: 7303-7.
16. Bryant HE1, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913-7.
17. Starita LM and Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr. Opin. Cell. Biol. 2003; 15: 345-350.
18. Holloman WK: Unraveling the mechanism of BRCA2 in ho-mologous recombination. Nat. Struct. Mol. Biol. 2011; 18: 748-754. doi: 10.1038/nsmb.2096.
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-15. doi: 10.1038/nature10166
20. Menear KA1, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC and Martin NM. 4-(3-(4-cyclopropanecar-bonylpiperazine-1-carbonyl)-4-fluorobenzyl)-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 2008; 51: 6581-91. doi: 10.1021/jm8001263.
21. Sessa C. Update on PARP-1 inhibitors in ovarian cancer. Ann. Oncol. 2011; 22: S72-6. doi: 10.1093/annonc/mdr528.
22. Fong PC1, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS and Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010 May 20; 28: 2512-9. doi: 10.1200/JCO.2009.26.9589.
23. Yamamoto N1, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X and Tamura T. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Can-cer. Sci. 2012; 103: 504-9. doi: 10.1111/j.1349-7006.2011.02179.x.
24. Rajan A1, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD and Giaccone G. A phase I combination study of olaparib with cispl-atin and gemcitabine in adults with solid tumors. Clin. Cancer. Res. 2012; 18: 2344-51. doi: 10.1158/1078-0432.CCR-11-2425.
25. Chan N, Bristow RG. Contextual synthetic lethality and/or loss of heterozygosity: tumour hypoxia and modification of DNA repair. Clin. Cancer. Res. 2010; 16: 4553-60. doi: 10.1158/1078-0432.CCR-10-0527.
26. Dean E1, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P and Ranson M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in pa-tients with advanced solid tumours Br J Cancer. 2012; 106: 468-74. doi: 10.1038/bjc.2011.555.
27. van der Noll R, Ang JE, Jager A, Marchetti S., Mergui-Roelvink M, De Bono J S, Lolkema M, Brunetto A, Arkenau HT, De Jonge M J, van der Biessen D, Tchakov I, Bowen K and Jan H. M. Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. J. Clin. Oncol 2013; 31: ab-str. 2579.
28. Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S and Morrison J: DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database Syst. Rev. 2010; 6: CD007929. doi: 10.1002/14651858.CD007929.pub2.
29. Audeh MW1, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M and Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 24; 376: 245-51. doi: 10.1016/S0140-6736(10)60893-8.
30. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh W, Friedlander M, Balmaña J, Mitchell G, Fried G, Bowen K, Field-ing A and Domchek S M. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2mutation: An open-label phase II study. J. Clin. Oncol. 2013; 31: abstr 11024. doi: 10.1200/JCO.2014.56.2728.
31. Gelmon KA1, Tischkowitz M, Mackay H, Swenerton K, Ro-bidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J and Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multi-centre, open-label, non-randomised study. Lancet 2011; 12: 852-61. doi: 10.1016/S1470-2045(11)70214-5.
32. Liu X1, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Har-lan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF and Shoemaker AR. Iniparib nonselectively modifies cysteine-contain-ing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. 2012 Jan 15; 18: 510-23. doi: 10.1158/1078-0432.CCR-11-1973.
33. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME and Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topote-can. J. Clin. Oncol. 2001; 19: 3312-22.
34. Adams SF1, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B and Rubin SC. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gy-necol. Oncol. 2011; 123: 486-91. doi: 10.1016/j.ygyno.2011.08.032.
35. Kaye SB1, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Sa-fra T, Vergote I, Wickens M, Lowe ES, Carmichael J and Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymer-ase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 2012; 30: 372-9. doi: 10.1200/JCO.2011.36.9215.
36. Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J and Matulonis U. Olapa-rib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012; 366: 1382-92. doi: 10.1056/NEJ-Moa1105535.
37. Ledermann J A, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G J S, ScottC L, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Macpherson E, Dougherty B, Jürgensmeier J M, Orr M and Matulonis U. Olaparib maintenance therapy in pa-tients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J. Clin. Oncol. 2013; 31 abstr 5505. doi:10.1016/S1470-2045(14)70228-1.
38. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Ro-bidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J and Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, mul-ticentre, open-label, non-randomised study. Lancet Oncol. 2011; 12: 852-61. doi:10.1016/S1470-2045(11)70214-5.
39. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC and Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned ret-rospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 2014; 15:852-61. doi: 10.1016/S1470-2045(14)70228-1.
40. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P and Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibi-tor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-neg-ative breast cancer. Eur. J. Cancer. 2013;49:2972-8. doi: 10.1016/j.ejca.2013.05.020.
41. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hu-bert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A and Domchek SM. Olaparib monotherapy in patients with ad-vanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 2015;33:244-50. doi: 10.1200/JCO.2014.56.2728.
42. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC and Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian can-cer: a randomized phase 2 trial. Lancet Oncol. 2015;16:87-97. doi:10.1016/S1470-2045(14)71135-0.
43. Kun E, Mendeleyev J, Hakam A and Kirsten E. Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide. Mol. Med. Rep. 2009; 2: 739-42. doi: 10.3892/mmr_00000165.
44. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM and Bradley C: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011; 364: 205-14. doi: 10.1056/NEJMoa1011418.
45. O'Shaughnessy J SL, Danso MA, Rugo RH, Miller K, Yard-ley DA, Carlson RW, Finn RS, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A and Winer EP. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol. 2011; 29:abstract 1007.
46. Aghajanian C, Sill MW, Secord AA, Powell MA and Steinhoff M. Iniparib plus paclitaxel and carboplatin as initial treatment of ad-vanced or recurrent uterine carcinosarcoma: a Gynecologic Oncol-ogy Group Study. Gynecol. Oncol. 2012; 126: 424-7. doi: 10.1016/j.ygyno.2012.05.024. E
47. Mahany JJ, Lewis N and Heath EI. A phase IB study evaluat-ing BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J. Clin. Oncol. 2008; 26:abstract 3579,50.
48. S. Kopetz, M. M. Mita, I. Mok, Sankhala KK, Moseley J, Sherman BM, Bradley CR and Tolcher AW. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J. Clin. Oncol., ASCO Annual Meeting Proceedingsn (Post-Meeting-Edi-tion). 2008;26,3577.
49. Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantino-poulos P, Stallings TE, Bradley CR and Birrer MJ. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol. 2011; 29: abstract 5004.
50. Birrer MJ, P Konstantinopoulos P, Penson RT, Roche M, Ambro-sio A, Stallings TE, Matulonis Un and Bradley CR. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J. Clin. Oncol. 2011; 29: abstract 5005.
51. Zaremba T and Curtin NJ. PARP inhibitor development for sys-temic cancer targetin. Anticancer Agents Med. Chem. 2007; 7: 515-523. doi: 10.2174/187152007781668715
52. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL,Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, HristovB, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavro-poulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL and David J. Frost. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in pre-clinical tumor models. Clin. Cancer Res. 2007; 13: 2728-2737. doi: 10.1158/1078-0432.CCR-06-3039
53. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010; 10: 293-301. doi: 10.1038/nrc2812.
54. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Col-lins J, Steinberg SM, Eliopoulos H,Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE and Doroshow JH. Phase 0 clini-cal trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 2009; 27: 2705-2711. doi: 10.1200/JCO.2008.19.7681.
55. Parise RA, Shawaqfeh M, Egorin MJ and Beumer JH. Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly (ADP-ribose) polymerase. J. Chromatogr. B An-alyt. Technol. Biomed Life Sci. 2008; 872: 141-7. doi: 10.1016/j.jchromb.2008.07.032.
56. Kummar S, Chen AP, Ji JJ, Allen D, Egorin M J, Gandara D R, Lenz, H, Morgan R, Newman E M and Doroshow J H. A phase I study of ABT-888 (a) in combination with metronomic cyclophos-phamide (c) in adults with refractory solid tumors and lymphomas. ASCO 2010; 2605.
57. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Cart-er J, Stotler H, Rubinstein L,Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE and Doroshow JH. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011; 71: 5626-34. doi: 10.1158/0008-5472.CAN-11-1227.
58. YadavA, KumarB, TeknosTN and KumarP. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulat-ing ERCC-1 and XRCC-1DNA repair proteins. Mol. Cancer Ther. 2011; 10: 1241-51. doi: 10.1158/1535-7163.MCT-11-0004.
59. Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scar-dina A, Joffe C, Petito E, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Siu LL and Azad NS. A Phase I study of ve-liparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid ma-lignancies and peritoneal carcinomatosis. Clin. Cancer Res. 2015; 21:68-76. doi: 10.1158/1078-0432.CCR-14-1552.
60. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A and Swisher EM. A phase II evaluation of the potent, highly selec-tive PARP inhibitor veliparib in the treatment of persistent or recur-rent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation-An NRG Oncology/Gynecologic Oncology Group study. Gynecol. On-col. 2015; 137: 386-91. doi: 10.1016/j.ygyno.2015.03.042.
61. Shapiro G, Kristeleit R, Middleton M, Burris H, Rhoda Molife L, Evans J, Wilson R, LoRusso P, Spicer J, Dieras V, Pate M, Dominy E, Simpson D, Giordano H, Allen A R, Jaw-Tsai S S and Plummer R. Pharmacoki-netics of orally administered rucaparib in patients with advanced solid tumors. Proceedings of AACR/NCI/EORTC targeted therapies meeting; 2013 (abstract 218).
62. Kristeleit R, Burris H, LoRusso P, Patel M, Giordano H, Isaac-son J, Borrow J, Allen A, Jaw-Tsai S, and Shapiro G. Phase I study of continuous oral rucaparib: analysis of patient subgroup with ovar-ian/peritoneal cancer. Proceedings from the European Society of Gynecologic Oncology meeting; 2013 (abstract 124).
63. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D,Robson L and Calvert H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2008; 14:7917-23. doi: 10.1158/1078-0432.CCR-08-1223.
64. Rhoda Molife L, Roxburgh P, Wilson R H, Gupta A, Middleton M R, Evans T R E, Ogilvie Michie C, Mateo J, Crawford D, McKin-lay Eatock M, Saka W, Cresti N, Drew Y, Giordano H, Despain D, Simpson D, Allen A R, Jaw-Tsai S and Plummer R. A phase I study of oral rucaparib in combination with carboplatin. Proceedings from the European Cancer Congress; 2013 (abstract 824).
65. Coupe N, Roxburgh P, Drew Y, Molife LR, Wilson R, Spicer J, Spicer J, Gupta A, Simpson D, Giordano H and Plummer R. Phase I study of oral or intravenous rucaparib in combination with plat-inum-containing chemotherapeutic regimens: analysis of patients with ovarian or peritoneal cancers. Eur Soc of Gyn Onc Proceed-ings; 2013 (abstract 155).
66. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, Scarpelli R, Schultz-Fademrecht C, Toniatti C and Rowley M. Discovery of 2-(4-((3S)-piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J. Med. Chem. 2009; 52: 7170-85. doi: 10.1021/jm901188v.
67. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS and Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14: 882-92. doi: 10.1016/S1470-2045(13)70240-7.
68. Flynn M, Shapiro G, LoRusso P, et al. A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors. ESMO Annu. Meet. Abstract 881 (2013).
69. Kristeleit R, Frommer R, Burris H, et al. Phase 1 / 2 Study of Oral Rucaparib: Updated Phase 1 and Preliminary Phase 2 Results. Annals of Oncology 2014, 25 (suppl4): iv305-iv326. 10.1093/an-nonc/mdu338.
70. Roscilli G, Gavory G, Lamartin S, et al. PARP inhibitor MK-4827 is synthetic lethal for tumors with homologous recombination defects associated with ATM-deficiency, PTEN-deletion and micro-satellite instability (MSI). Annual Meeting of the American Associa-tion for Cancer Research; Washington, DC, USA;2010 April 17-21.
71. Cardnell RJ1, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, and Byers LA. Proteo-mic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013. 19:6322-8. doi: 10.1158/1078-0432.CCR-13-1975.
72. De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, et al. First-in-human trial of the novel PARP inhibi-tor BMN 673 in patients with solid tumors. J Clin Oncol 2013;31 (Suppl.; abstr 2580).
73. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N and Tani-guchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer. Res. 2008; 68: 2581-6. doi: 10.1158/0008-5472.CAN-08-0088
74. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N and Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120. doi: 10.1038/nature06633.
75. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Ny-gren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A,O'Connor MJ, Martin NM, Borst P and Jonkers J. High sensitivity of BRCA 1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in comination with plati-num drugs. Proc. Natl. Acad. Sci. USA 2008; 105:17079-17084. doi: 10.1073/pnas.0806092105.
76. Lee SA, Roques C, Magwood AC, Masson JY and Baker MD. Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair (Amst) 2009; 8: 170-81. doi: 10.1016/j.dnarep.2008.10.002.
77. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR. New colorimet-ric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer. Inst. 1990; 82:1107-12. doi: 10.1093/jnci/82.13.1107
78. Ang J, Yap TA and Fong P. Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly (ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). J. Clin. Oncol. 2010; 28: abstract 5041.
79. Konstantinopoulos PA1, Spentzos D, Karlan BY et Taniguchi T, Fountzilas E, Francoeur N, Levine DA andCannistra SA. Gene expression profile of BRCAness that correlates with responsive-ness to chemotherapy and with outcome inpatients with epithelial ovarian cancer. J. Clin. Oncol. 2010; 28: 3555-61. doi: 10.1200/JCO.2009.27.5719.
80. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ andCur-tin NJ. Development of a functional assay for homologous recom-bination status in primary cultures of epithelial ovarian tumour and correlation with sensitivity to poly (ADP-ribose) polymerase inhibi-tors. Clin. Cancer Res. 2010; 16: 2344-51. doi: 10.1158/1078-0432.CCR-09-2758.
81. Liu X1, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rod-riguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo and Giranda VL. An enzyme-linked immunosorbent poly (ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal. Biochem. 2008; 381: 240-247. doi: 10.1016/j.ab.2008.07.007.
82. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH and Pommier Y. Histone gammaH2AX and Poly (ADP-Ribose) as Clinical Pharmacodynamic Bio-markers. Clin. Cancer Res 2010; 16: 4532-42. doi: 10.1158/1078-0432.CCR-10-0523.
83. Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ and Cam-phausen K. High throughput evaluation of gamma-H2AX. Radiat. Oncol. 2009; 4: 31. doi: 10.1186/1748-717X-4-31
84. Secord AA1, Barnett JC, Ledermann JA, Peterson BL, Myers ER and Havrilesky LJ. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Int. J. Gynecol. Cancer 2013; 23: 846-52. doi: 10.1097/IGC.0b013e31829527bd
85. Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Pier-luigi Benedetti Panici and Marianna Nuti. Immunologic Systemic Effect of Neoadjuvant Chemotherapy Requires Investigation Be-fore Tumor-Associated Lymphocytes Can Be Introduced in Breast Cancer Treatment Algorithm. J Clin Oncol 2010; 28: e471-2. doi: 10.1200/JCO.2010.27.9984.
86. Li, Y., Ahmad, A., Sarkar and F. H., ASPP and iASPP: Implica-tion in cancer development and progression. Cell. Mol. Biol. 2015, 61(6): 2-8.
87. Masood, N., Qureshi, M. Z. and Yasmin, A., Association of NOTCH with different microRNAs in head and neck cancer. Cell. Mol. Biol. 2015, 61(6): 9-16.
88. Amirkhah, R., Farazmand, A., Irfan-Maqsood, M., Wolkenhau-erand, O. and Schmitz, U., The role of microRNAs in the resistance to colorectal cancer treatments. Cell. Mol. Biol. 2015, 61(6): 17-23.
89. Wang, Z., Chen, J. and Capobianco, A. J., The Notch signal-ing pathway in esophageal adenocarcinoma. Cell. Mol. Biol. 2015, 61(6): 24-32.
90. Limami, Y., Pinon, A., Riaz, A. and Simon, A., TRAIL and tar-geting cancer cells: between promises and obstacles. Cell. Mol. Biol. 2015, 61(6): 33-38.
91. Silva Galbiatti-Dias, A. L., Pavarino, É. C., Kawasaki-Oyama, R. S., Maniglia, J. V., Maniglia, E. J. V. and Goloni Bertollo, E. M., Cancer stem cells in head and neck cancer: A Mini Review. Cell. Mol. Biol. 2015, 61(6): 39-43.
92. Attar, R., Tabassum, S., Fayyaz, S., Ahmad, M. S., Nogueira, D. R., Yaylim, I., Timirci-Kahraman, O., Kucukhuseyin, O., Cacina, C., Farooqi, A. A. and Ismail, M., Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites. Cell. Mol. Biol. 2015, 61(6): 62-68.
93. Hsu, Y-C., Hsieh, Y-H., Liao, C-C., Chong, L-W., Lee, C-Y., Yu, Y-L. and Chou, R-H., Targeting post-translational modifications of histones for cancer therapy. Cell. Mol. Biol. 2015, 61(6): 69-84.
94. Chong, L-W., Chou, R-H., Liao, C-C., Lee, T-F., Lin, Y., Yang, K-C. and Hsu, Y-C. Saturated fatty acid induces cancer stem cell-like properties in human hepatoma cells. Cell. Mol. Biol. 2015, 61(6): 85-91.
95. Smina, T. P., Mohan, A., Ayyappa, K. A., Sethuraman, S. and Krishnan, U. M., Hesperetin exerts apoptotic effect on A431 skin carcinoma cells by regulating mitogen activated protein kinases and cyclins. Cell. Mol. Biol. 2015, 61(6): 92-99.
96. Ahmadi, M., Jafari, R., Marashi, S. A. and Farazmand, A., In-direct role of microRNAs and transcription factors in the regulation of important cancer genes: A network biology approach. Cell. Mol. Biol. 2015, 61(6): 100-107.
97. Zahoor, A., Mansoor, Q., Farooqi, A. A., Fayyaz, S., Naz, G. and Ismail, M., Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani popula-tion. Cell. Mol. Biol. 2015, 61(6): 108-112.